Drug intelligence / Profile preview

KK8005

Development stage: Unknown
Lead developer: Kyowa Kirin
Administration: Subcutaneous

Overview

KK8005 is an investigational therapeutic being developed by Kyowa Kirin for the treatment of X-linked hypophosphatemia (XLH). XLH is a rare genetic disorder characterized by excessive renal phosphate wasting due to elevated levels of fibroblast growth factor 23 (FGF23), leading to chronic hypophosphatemia and impaired bone mineralization. While Kyowa Kirin previously developed and marketed burosumab (KRN23), a monoclonal antibody targeting FGF23, KK8005 represents a newer addition to their pipeline. It is currently being evaluated in Phase 1/2 clinical trials to assess its safety, tolerability, and pharmacodynamic effects on serum phosphorus levels in adult patients with XLH.

Beyond the preview

Go deeper on KK8005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KK8005.

Explore the full profile